In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 1, 2013, Pages 218-230

  Slack, Robert J ^a   Barrett, Victoria J ^a   Morrison, Valerie S ^a   Sturton, Richard G ^b   Emmons, Amanda J ^a   Ford, Alison J ^a   Knowles, Richard G ^a,c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c Stevenage Bioscience Catalyst   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; CYCLIC AMP; FORMOTEROL; INDACATEROL; ISOPRENALINE; SALBUTAMOL; SALMETEROL; SOTALOL; VILANTEROL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRONCHODILATING ACTIVITY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; FEMALE; GUINEA PIG; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; RADIOASSAY; TREATMENT DURATION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-3 RECEPTOR ANTAGONISTS; ALBUTEROL; ANIMALS; BENZYL ALCOHOLS; BINDING, COMPETITIVE; CELL MEMBRANE; CELLS, CULTURED; CHLOROBENZENES; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DATA INTERPRETATION, STATISTICAL; FLUORESCENCE POLARIZATION; GUINEA PIGS; HUMANS; KINETICS; PROPANOLAMINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, BETA-2;

EID: 84871697898     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.198481     Document Type: Article

References (39)

1. 2-adrenoceptor agonist bronchodilator. Life Sci 52:2145-2160.
2. Anderson GP, Lindén A, and Rabe KF (1994) Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 7:569-578. (Pubitemid 24099018)
3. 3 adrenoceptors. Br J Pharmacol 144:317-322.
4. 3- adrenoceptors. Br J Pharmacol 160:1048-1061.
5. 2- adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 104:665-671.
6. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O'Byrne P, Pedersen SE, et al. (2008) Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31:143-178.
7. 2 adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 317:762-770.
8. Broadley KJ (2006) β-adrenoceptor responses of the airways: for better or worse? Eur J Pharmacol 533:15-27.
9. Busse WW and Lemanske RF, Jr (2001) Asthma. N Engl J Med 344:350-362. (Pubitemid 32107645)
10. Casarosa P, Kollak I, Kiechle T, Ostermann A, Schnapp A, Kiesling R, Pieper M, Sieger P, and Gantner F (2011) Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther 337: 600 -609.
11. 2- adrenoceptor agonists: current and future direction. Br J Pharmacol 163:4-17.
12. 2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 23: 257-267.
13. Celli BR and MacNee W; ATS/ERS Task Force (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23:932-946. (Pubitemid 38807371)
14. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
15. Coleman RA, Johnson M, Nials AT, and Vardey CJ (1996) Exosites: their current status, and their relevance to the duration of action of long-acting β2-adrenoceptor agonists. Trends Pharmacol Sci 17:324-330. (Pubitemid 26302709)
16. Contreras ML, Wolfe BB, and Molinoff PB (1986) Thermodynamic properties of agonist interactions with the beta adrenergic receptor-coupled adenylate cyclase system. I. High- and low-affinity states of agonist binding to membrane-bound beta adrenergic receptors. J Pharmacol Exp Ther 237:154-164. (Pubitemid 16116359)
17. Cullum VA, Farmer JB, Jack D, and Levy GP (1969) Salbutamol: a new, selective β-adrenoceptive receptor stimulant. Br J Pharmacol 35:141-151.
18. 2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest 142:119-127.
19. Hill AV (1909) The mode of action of nicotine and curari, determined by the form of the contraction curve and the method of temperature coefficients. J Physiol 39: 361-373.
20. Hirst C, Calingaert B, Stanford R, and Castellsague J (2010) Use of long-acting β-agonists and inhaled steroids in asthma: meta-analysis of observational studies. J Asthma 47:439-446.
21. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6:65-70.
22. Johnson EN and Druey KM (2002) Heterotrimeric G protein signaling: role in asthma and allergic inflammation. J Allergy Clin Immunol 109:592-602. (Pubitemid 34327182)
23. Johnson M, Butchers PR, Coleman RA, Nials AT, Strong P, Sumner MJ, Vardey CJ, and Whelan CJ (1993) The pharmacology of salmeterol. Life Sci 52:2131-2143.
24. Kardos P and Keenan J (2006) Tackling COPD: a multicomponent disease driven by inflammation. Med Gen Med 8:54.
25. Lotvall J, Bateman ED, Bleecker ER, Busse WW, Woodcock A, Follows R, Lim J, Stone S, Jacques L, and Haumann B (2012) 24h duration of the novel LABA vilanterol trifenatate in asthma patients treated with ICSs. Eur Respir J 40:570-579.
26. 2-agonists in the management of COPD: biological and pharmacological aspects. Drug Discov Today 17:496-504.
27. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, and Dorinsky PM; SMART Study Group (2006) The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129:15-26. (Pubitemid 43265239)
28. 2-adrenoceptor. Pulm Pharmacol Ther 24: 247-255.
29. 2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem 53:4522-4530.
30. 2-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol 382:255-263.
31. 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
32. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85. (Pubitemid 16258399)
33. 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 324:270-275.
34. Summerhill S, Stroud T, Nagendra R, Perros-Huguet C, and Trevethick M (2008) A cell-based assay to assess the persistence of action of agonists acting at recombinant human b2 adrenoceptors. J Pharmacol Toxicol Methods 58:189-197.
35. 2- adrenoceptor agonist salmeterol. Br J Pharmacol 158:183-194.
36. Tashkin DP (2005) Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease? Curr Opin Pulm Med 11:121-128.
37. Toews ML, Harden TK, and Perkins JP (1983) High-affinity binding of agonists to β-adrenergic receptors on intact cells. Proc Natl Acad Sci USA 80:3553-3557. (Pubitemid 13063119)
38. Waldeck B (2002) b-adrenoceptor agonists and asthma-100 years of development. Eur J Pharmacol 445:1-12.
39. 3H] mepyramine and related compounds to the histamine H1 receptor. Mol Pharmacol 23:60-66.